Use of salt of an acetylsalicylic acid for the treatment of viral infections
The invention relates to a method of use of a composition comprising a salt of the o-acetylsalicylic acid with a basic amino acid for producing a pharmaceutical composition for the prophylaxis or treatment of viral infections of humans or of animals, in particular mammals and birds.
1. A method for the treatment of an influenza A viral infection in a human or animal, wherein a pharmaceutical composition is administered to said human or animal, wherein said pharmaceutical composition comprises:
a salt of o-acetylsalicylic acid with a natural or non-natural basic amino acid; and
a salt of o-acetylsalicylic acid with glycine,
wherein the pharmaceutical composition is an aerosol formulation, and wherein said aerosol formulation is administered aerogenically through the nose or mouth to said human or animal in an amount effective to treat said influenza A viral infection.
2. The method of claim 1 , wherein the basic amino acid is selected from the group consisting of lysine, arginine, omithine, diaminobutyric acid, and mixtures of such amino acids.
3. The method of use according to claim 2 , wherein the basic amino acid is D-lysine, L-lysine or a mixture of D-lysine and L-lysine.
4. The method of claim 1 , wherein the influenza A virus is of H5 or H7 type.
5. The method of claim 1 , wherein the pharmaceutical composition is a galenic preparation comprising a liquid or aqueous composition.
6. The method of claim 5 , wherein the pharmaceutical composition is an aqueous composition that is a 0.1 to 5 M, 0.1 to 3 M, or 1 to 3 M aqueous solution of said salt.
7. The method of claim 5 , wherein the pharmaceutical composition is an aqueous composition that is a 0.01 to 100 mM or 0.1 to 10 mM aqueous solution of said salt.
8. The method of claim 1 , wherein the composition is arranged in a pharmaceutically compatible tank with a vaporizer or nebulizer.
9. The method of claim 8 , wherein the tank is prepared for the adjustment of an inhalation flow of less than 1,000 ml/s, less than 500 ml/s, or less than 300 ml/s, and of a breathing volume of at least 10-%, at least 30-%, at least 50-%, or up to 95-%, in reference to the inspiration capacity of a patient.
10. The method of claim 1 , wherein at least 10 mg, at least 50 mg, at least 100 mg, or up to more than 200 mg, of the salt of o-acetylsalicylic acid is administered aerogenically.
11. The method of claim 1 , wherein an inhalation flow of the aerogenically administered aerosol formulation is adjusted to less than 1,000 ml/s, less than 500 ml/s, or less than 300 ml/s is, and wherein a breathing volume of the aerogenically administered aerosol formulation is adjusted to at least 20-%, at least 30-%, at least 50-%, or up to 95-%, in reference to the inspiration capacity of a patient.
12. The method of claim 1 , wherein the aerosol formulation is administered by means of an inhalation device with a supply tank and an aerosol generator connected to the supply tank.
13. The method of claim 12 , wherein the inhalation device further comprises a control or regulation means for the control or regulation of the inhalation flow and of the breathing volume, wherein the control or regulation means are preferably adjusted to less than 1,000 ml/s, less than 500 ml/s, or less than 300 ml/s is, and wherein the breathing volume is adjusted to at least 20%, at least 30%, at least 50%, or up to 95%, in reference to the inspiration capacity of a patient.
14. The method of claim 1 , wherein the salt of o-acetylsalicylic acid is a mono-acetylsalicylate.
15. The method of claim 1 , wherein the aerosol formulation is administered aerogenically in less than 5 min, less than 2 min, or less than 1 min.